104 related articles for article (PubMed ID: 24286424)
1. Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo.
Zhou JH; Yao YS; Wang LX; Wang J; Li YH; Jiang MM; Zhou MH; Gao XN; Li RS; Wang LL; Yu L
Chin Med J (Engl); 2013 Dec; 126(23):4552-6. PubMed ID: 24286424
[TBL] [Abstract][Full Text] [Related]
2. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
[TBL] [Abstract][Full Text] [Related]
3. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
[TBL] [Abstract][Full Text] [Related]
4. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
5. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
[TBL] [Abstract][Full Text] [Related]
6. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
7. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
[TBL] [Abstract][Full Text] [Related]
8. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
Guo ZS; Hong JA; Irvine KR; Chen GA; Spiess PJ; Liu Y; Zeng G; Wunderlich JR; Nguyen DM; Restifo NP; Schrump DS
Cancer Res; 2006 Jan; 66(2):1105-13. PubMed ID: 16424047
[TBL] [Abstract][Full Text] [Related]
9. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
[TBL] [Abstract][Full Text] [Related]
11. 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.
Wachowska M; Gabrysiak M; Muchowicz A; Bednarek W; Barankiewicz J; Rygiel T; Boon L; Mroz P; Hamblin MR; Golab J
Eur J Cancer; 2014 May; 50(7):1370-81. PubMed ID: 24559534
[TBL] [Abstract][Full Text] [Related]
12. Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic T lymphocyte function in a mouse mammary model.
Sun JZ; Gao L; Gao L; Wang W; Du N; Yang J; Wan L; Liu F; Wang LL; Yu L
Biomed Res Int; 2013; 2013():196894. PubMed ID: 24294600
[TBL] [Abstract][Full Text] [Related]
13. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
14. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.
Terracina KP; Graham LJ; Payne KK; Manjili MH; Baek A; Damle SR; Bear HD
Cancer Immunol Immunother; 2016 Sep; 65(9):1061-73. PubMed ID: 27416831
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
[TBL] [Abstract][Full Text] [Related]
16. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Blagitko-Dorfs N; Ford LA; Naqash R; Lübbert M; Karpf AR; Nemeth MJ; Griffiths EA
Oncotarget; 2016 Mar; 7(11):12840-56. PubMed ID: 26883197
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
18. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
Zhou Q; Guo AL; Xu CR; An SJ; Wang Z; Yang SQ; Wu YL
Clin Exp Immunol; 2008 Sep; 153(3):392-400. PubMed ID: 18803763
[TBL] [Abstract][Full Text] [Related]
19. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
[TBL] [Abstract][Full Text] [Related]
20. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
